

# Roberta Parente

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400695/publications.pdf>

Version: 2024-02-01

33  
papers

894  
citations

567281

15  
h-index

477307

29  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1207  
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
2	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Thrombosis Research</i> , 2022, 209, 69-74.	1.7	8
3	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. <i>Journal of Autoimmunity</i> , 2022, 129, 102832.	6.5	3
4	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
5	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	3.5	14
6	Vascular endothelial growth factors and angiopoietins as new players in mastocytosis. <i>Clinical and Experimental Medicine</i> , 2021, 21, 415-427.	3.6	12
7	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. <i>British Journal of Haematology</i> , 2021, 193, 845-848.	2.5	6
8	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	3.8	13
9	Orofacial granulomatosis: Clinical and therapeutic features in an Italian cohort and review of the literature. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2189-2200.	5.7	8
10	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.7	14
11	Screening for Hereditary Alpha-Trypsinemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. <i>Blood</i> , 2021, 138, 1500-1500.	1.4	1
12	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	3.5	18
13	Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder. <i>Clinical and Molecular Allergy</i> , 2021, 19, 26.	1.8	15
14	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
15	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	3.5	30
16	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
17	Flow-mediated dilation shows impaired endothelial function in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1106-1111.	2.9	9
18	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	2.2	8

#	ARTICLE	IF	CITATIONS
19	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	4.6	101
20	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	3.8	112
21	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
22	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 318-323.	1.0	21
23	Biomarkers for evaluation of mast cell and basophil activation. <i>Immunological Reviews</i> , 2018, 282, 114-120.	6.0	73
24	Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. <i>International Archives of Allergy and Immunology</i> , 2018, 175, 126-135.	2.1	45
25	Risk Factors and Cofactors for Severe Anaphylaxis. <i>Current Treatment Options in Allergy</i> , 2018, 5, 204-211.	2.2	3
26	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 208-218.	3.8	13
27	Pitfalls in anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 382-386.	2.3	7
28	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	1.8	15
29	Evaluation of vaccination safety in children with mastocytosis. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 93-95.	2.6	28
30	Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care. <i>Acta Dermato-Venereologica</i> , 2017, 97, 81-85.	1.3	21
31	Mast cells as effector cells of innate immunity and regulators of adaptive immunity. <i>Immunology Letters</i> , 2016, 178, 10-14.	2.5	84
32	Urticarial Vasculitis. A Review of the Literature. , 2016, , 321-329.		0
33	Anaphylaxis and cardiovascular diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 309-315.	2.3	34